Wednesday, July 8, 2026

pharma · Diabetes Mellitus, Type 2 · Sickle Cell Disease · CYCN

Cyclerion Therapeutics

Cyclerion Therapeutics patent portfolio — 17 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Gainesville, USA HQ
1990 Founded
14 Employees
Public company Type
CYCN · NYSE Ticker
Company details
Status
Public
HQ
Gainesville, USA
Founded
1990
Employees
14
Programs
9
Drugs
2
Patents
17
Intelligence · Patents

Cyclerion Therapeutics patents

17 pharmaceutical patents indexed for Cyclerion Therapeutics. 0 expire within 24 months.

Cyclerion Therapeutics has 17 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

Patent portfolio

  1. US 12247025

    Processes for preparation of soluble guanylate cyclase stimulators

    Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 11834444

    Processes for preparation of soluble guanylate cyclase stimulators

    Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 11731977

    SGC stimulators

    Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 11690828

    Treatment of CNS diseases with sGC stimulators

    Expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 11572358

    Solid forms of an sGC stimulator

    Expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 11466015

    Crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine as sGC stimulators

    Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 11389449

    Treatment of metabolic syndrome with an sGC stimulator

    Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 11357777

    Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH)

    Expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 11207323

    sGC stimulators

    Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 11180493

    SGC stimulators

    Expires Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. US 10927136

    Phosphorus prodrugs of pyrazolo-substituted pyrimidine sGC stimulators

    Expires Mon Feb 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  12. US 10889577

    Solid forms of an sGC stimulator

    Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  13. US 10858363

    SGC stimulators

    Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  14. US 10844064

    sGC stimulators

    Expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  15. US 10639308

    sGC stimulators

    Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  16. US 10517874

    sGC stimulators

    Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  17. US 10472363

    SGC stimulators

    Expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Cyclerion Therapeutics have?

17 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Cyclerion Therapeutics patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.